good idea ! it will depend on EV multiple that BP will apply to our business. Now if w we assume say 5 therapeutic suites at at say assessed revenue of $ 5b a piece pa. I actually think in hindsight that we will have a breakup value proposition…
I note that big whales - Ie JNJ are very quiet in the oncology space. My valuation will ranges from a wide scope $ 5> $11 aud per share, depending on the successful rev potential of the all respective therapies… what say you fellow HCs ? What’s your logic ?
good idea ! it will depend on EV multiple that BP will apply to...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
0.002(3.92%) |
Mkt cap ! $387.9M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.3¢ | 5.0¢ | $605.4K | 11.73M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 455000 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 1913821 | 7 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |